Inclusion Criteria

DISEASE CHARACTERISTICS: Immunophenotypically proven B-cell acute lymphoblastic leukemia
Relapsed at least once following standard induction chemotherapy M1, M2, M3 No CNS disease
(including clinical signs of CNS disease) OR Immunophenotypically proven B-cell
non-Hodgkin's lymphoma Refractory or resistant disease following up to 3 prior courses of
combination chemotherapy Relapsed following bone marrow transplantation No CNS disease No
AIDS-related or HTLV-1 associated lymphomas NHL must be one of the following types: Small
lymphocytic lymphoma (consistent with chronic lymphoblastic leukemia) Follicular small
cleaved cell lymphoma Follicular mixed cell lymphoma Follicular large cell lymphoma
Diffuse small cleaved cell lymphoma Diffuse mixed cell lymphoma Diffuse large cell
lymphoma Immunoblastic large cell lymphoma Diffuse small noncleaved cell lymphoma Must
have greater than 20% CD19 antigen positive blasts in the bone marrow, peripheral blood,
or biopsy (for NHL) at first diagnosis or relapse (non-T cell ALL with CD19 positivity
pending allowed) Patients who have relapsed after bone marrow transplantation are eligible
(no active acute or chronic graft versus host disease involving more than the skin)

PATIENT CHARACTERISTICS: Age: 80 and under Performance status: Karnofsky 60-100% Zubrod
0-2 Life expectancy: At least 2 months Hematopoietic: Granulocytopenia, anemia, and/or
thrombocytopenia allowed Hepatic: Bilirubin no greater than 1.5 times upper limit of
normal (ULN) SGOT or SGPT less than 2.5 times ULN Renal: Creatinine no greater than 1.5
times ULN OR Creatinine clearance or radioisotope GFR at least 70 mL/min Cardiovascular:
Shortening fraction at least 27% by echocardiogram OR Cardiac ejection fraction greater
than 50% by echocardiogram or gaited radionuclide Pulmonary: No dyspnea at rest No
exercise intolerance No clinical evidence of significant restrictive pulmonary disease
Pulse oximetry greater than 94% FEV1 or FVC greater than 60% DLCO at least 65 Other: Not
pregnant or nursing Negative pregnancy test Fertile patients must use effective
contraception during and for 2 months after study HIV negative No uncontrolled diabetes
mellitus No other serious uncontrolled medical condition No active uncontrolled infection
requiring systemic antibiotics or antifungal medications Prior CNS toxicity no greater
than grade 1

PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Recovered from
prior biologic therapy Chemotherapy: See Disease Charactertistics At least 2 weeks since
prior chemotherapy (4 weeks since nitrosoureas) and recovered Endocrine therapy: At least
1 week since prior high dose steroid therapy and recovered Radiotherapy: Not specified
Surgery: Not specified